The investigation has pinpointed activated leukocyte cell adhesion molecule (ALCAM), ADP-ribosylation factor-like protein 6-interacting protein 1 (ARL6IP1), and cyclin G2 (CCNG2) as potential immunoprotective agents in breast cancer pathology, while antizyme Inhibitor 1 (AZIN1), myoferlin (MYOF), and transforming acidic coiled-coil containing protein 2 (TACC2) are implicated as potential oncogenes. Here, CCNG2 is linked to breast carcinoma.